Role of Combined [⁶⁸Ga]Ga-DOTA-SST Analogues and [¹⁸F]FDG PET/CT in the Management of GEP-NENs: A Systematic Review

• Main Authors: Luciano Carideo, Daniela Prosperi, Francesco Panzuto, Ludovica Magi, Maria Sole Pratesi, Maria Rinzivillo, Bruno Annibale, Alberto Signore
• Format: Article
• Language: English
• Published: MDPI AG 2019-07-01
• Series: Journal of Clinical Medicine
• Subjects: somatostatin scintigraphy; FDG; Gallium-68; NEN; GEP; NET
• Online Access: https://www.mdpi.com/2077-0383/8/7/1032
• ISSN: 2077-0383

Gastro-entero-pancreatic neuroendocrine neoplasia (GEP-NENs) are rare tumors, but their frequency is increasing. Neuroendocrine tumors normally express somatostatin (SST) receptors (SSTR) on cell surface, especially G1 and G2 stage tumors, but they can show a dedifferentiation in their clinical history as they become more aggressive. Somatostatin receptor imaging has previously been performed with a gamma camera using [¹¹¹In]In or [^99mTc]Tc-labelled compounds, while [⁶⁸Ga]Ga-labelled compounds and PET/CT imaging has recently become the gold standard for the diagnosis and management of these tumors. Moreover, in the last few years ¹⁸F-fluorodeoxyglucose ([¹⁸F]FDG) PET/CT has emerged as an important tool to define tumor aggressiveness and give relevant prognostic information, particularly when coupled with [⁶⁸Ga]Ga-labelled SST analogues PET/CT. This review focuses on the importance of combined imaging with [⁶⁸Ga]Ga-labelled SST analogues and [¹⁸F]FDG for the management of GEP-NENs.